The overall goal of this proposal is to support the principal investigator, Dr. Daniel Westreich, in becoming a leading health scientist in the study of pregnancy among HIV+ women in sub-Saharan Africa, with a particular focus on the effect of pregnancy on response to highly active antiretroviral therapy (HAART) in South Africa. Prevalence of HIV among pregnant women in South Africa is substantially higher than that among other adults. While responses to antiretroviral therapy during and after pregnancy with respect to issues of prevention of mother to child transmission of HIV, little is known about the effect of pregnancy itself on responses to therapy. Understanding the effect of pregnancy on maternal responses to HAART is essential to providing good clinical care to HIV+ women in Africa and elsewhere. To address these questions, this work proposes to examine the effect of pregnancy (both pregnancy present at time of initiation of therapy, and pregnancy which occurs after the initiation of therapy) on virologic responses to HAART, adherence to HAART, retention in care, immunologic responses to HAART, and clinical (AIDS/death) responses to HAART. Because it is impossible (and highly unethical) to randomize the exposure of pregnancy, this study will rely on high quality clinical data collected in the Themba Lethu Clinic in Johannesburg, South Africa, an urban antiretroviral therapy clinic associated with the Clinical HIV Research Unit at the University of the Witwatersrand. The Principal Investigator of the proposed work, Dr. Daniel Westreich, has a strong track record in producing high quality research in collaboration with investigators and clinicians at the Clinic. The analysis of these data will require the use of structural models, an advanced body of epidemiologic methods. Thus, during the mentored phase of this award, Dr. Westreich will work with Mentor Dr. Stephen R. Cole, an internationally recognized authority on structural models, to acquire these skills and to evaluate the effect of pregnancy on maternal virologic responses to HAART. This training will take place in the Department of Epidemiology at The University of North Carolina at Chapel Hill, an internationally renowned center of excellence in epidemiologic and public health research. Building on this training and experience, during the independent phase of the award Dr. Westreich will lead investigations to evaluate the impact of pregnancy on retention in care and adherence to HAART, and on immunologic and clinical responses to HAART. This work will answer a suite of key substantive questions around the impact of pregnancy on response to HAART in South Africa. In doing so, this work will dramatically increase the base of scientific and public health evidence on this important subject, most likely in a way which is generalizable to much of sub-Saharan Africa. In addition, this work and training will help Dr. Westreich develop as a health scientist, giving him expertise in the application of structural models and other epidemiologic methods for quantitative causal inference in complex longitudinal data.

Public Health Relevance

Despite extremely high prevalence of HIV among pregnant women in sub-Saharan Africa, little is known about the specific effect of pregnancy on response to highly active antiretroviral therapy in that region. This study will evaluate the effect of pregnancy at time of initiation of therapy and pregnancy occurring after the initiation of therapy on virologic, immunologic, and clinical responses to antiretroviral therapy, as well as on retention in care and adherence to antiretroviral therapy. We will evaluate these effects through the application of advanced epidemiologic methods (structural models) to high quality clinical data collected in the Themba Lethu Clinic in Johannesburg, South Africa, an urban antiretroviral therapy clinic associated with the Clinical HIV Research Unit at the University of the Witwatersrand.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Career Transition Award (K99)
Project #
1K99HD063961-01
Application #
7841117
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Mofenson, Lynne M
Project Start
2010-02-01
Project End
2010-09-23
Budget Start
2010-02-01
Budget End
2010-09-23
Support Year
1
Fiscal Year
2010
Total Cost
$73,417
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Maskew, Mhairi; Brennan, Alana T; Westreich, Daniel et al. (2013) Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) 22:113-20
Westreich, Daniel; Cole, Stephen R; Young, Jessica G et al. (2012) The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med 31:2000-9
Firnhaber, Cynthia; Westreich, Daniel; Schulze, Doreen et al. (2012) Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc 15:17382
Westreich, Daniel; Cole, Stephen R; Schisterman, Enrique F et al. (2012) A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. Stat Med 31:2098-109
Westreich, Daniel; Cole, Stephen R; Nagar, Shashi et al. (2011) Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One 6:e22778
Howe, Chanelle J; Cole, Stephen R; Westreich, Daniel J et al. (2011) Splines for trend analysis and continuous confounder control. Epidemiology 22:874-5
Naimi, Ashley I; Cole, Stephen R; Westreich, Daniel J et al. (2011) A comparison of methods to estimate the hazard ratio under conditions of time-varying confounding and nonpositivity. Epidemiology 22:718-23
Westreich, Daniel; Cole, Stephen R; Funk, Michele Jonsson et al. (2011) The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf 20:317-20